B cells are generally thought to promote SLE development by producing pathogenic autoantibodies, and immunotherapy targeting B cells is considered as an attractive treatment for SLE, such as therapeutic antibodies (Abs) against CD20 and CD22. Here, CD22 is linked to systemic lupus erythematosus.